YOQNEAM, Israel and SAN RAMON, California, August 26 /PRNewswire/ -- UltraShape, the global leader in non-invasive fat reduction and body contouring, announced today the appointment of Assaf Eyal as President and Chief Executive Officer.
Assaf most recently served as Executive Vice President at NUR Macroprinters, a manufacturer of super-wide format digital printers and inks, While at NUR, Assaf was a member of a small leadership team that led to a successful sale to HP. Previously, he served in various positions at Orbotech Ltd., (NASDAQ: ORBK) over a seventeen year period, most recently as Co-President of the Display Division and Corporate VP, a division that grew under his leadership to revenues of $150 million. He holds a B.Sc in Engineering and M.Sc in Management.
Michael Berman, Chairman of the Board of UltraShape, stated, "Assaf's strong background in sales, marketing, service and R&D will enable him to strengthen UltraShape's position as market leader in the field of non-invasive body contouring. We are very pleased that he will be joining us and we believe that under his leadership UltraShape will reach important new achievements as it strives to enhance its market share and develop next generation body contouring products."
"I am pleased to join UltraShape as it strives to grow its leadership position in the industry," Assaf said. "The potential of working with a first-rate management team and a cutting-edge technology make this an exciting opportunity."
About the UltraShape(R) Contour I
The UltraShape Contour I system, which is authorized for marketing outside the U.S., incorporates patented non-thermal selective focused ultrasound technology. Contour I, is the first scientifically and clinically proven non-invasive fat reduction and body contouring device for both men and women. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively disrupt fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact.
The UltraShape procedure is available in 57 countries and over 100,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software provides a pre-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments.
The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S. and the Contour Plus system is an investigational product limited by U.S. law to investigational use only.
UltraShape is redefining aesthetic medicine by developing,
manufacturing and marketing innovative non-invasive technologies for body
contouring. The company is dedicated to providing clinically proven safe
and effective solutions that enhance the lives of patients worldwide. The
UltraShape proprietary non-invasive body contouring technology is based on
focused ultrasound that targets and selectively disrupts fat cells without
affecting surrounding structures. Founded in 2000, UltraShape is a
privately held and venture backed company. The UltraShape system is not
approved by the FDA for marketing in the United States. For more
information visit http://www.ultrashape.com.
Paula Moggio / Vanessa Hughes
Porter Novelli Life Sciences
Gitam Porter Novelli
|SOURCE UltraShape Ltd.|
Copyright©2008 PR Newswire.
All rights reserved